Aspirin, Heparin, and New Antithrombotic Drugs as Adjuncts to Thrombolytic Therapy for Acute Myocaradial Infarction

Rapold, Hans J.

doi:10.1007/978-0-585-33754-8_29

Cited by 1 publication

(1 citation statement)

References 174 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, all available thrombolytic agents still have significant shortcomings, including the need for large therapeutic doses, limited fibrin specificity and, most importantly, significant associated bleeding tendency and reocclusion [73]. For example, treatment of acute myocardial infarction with thrombolytic therapy is associated with a failure to lyse the clot in 15%–50% of coronary thrombi, 10%–25% of successfully recanalised vessels re‐occlude and up to 2% of treated patients suffer from major bleeding complications [74,75].…”

Section: Clinical Utility Of Cpu Inhibition or A Role For Cpu In Vivo?mentioning

confidence: 99%

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Willemse

Heylen

Nesheim

et al. 2009

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Procarboxypeptidase U (TAFI) is a recently discovered plasma procarboxypeptidase that upon activation by thrombin or thrombin-thrombomodulin turns into a potent antifibrinolytic enzyme. Its prominent bridging function between coagulation and fibrinolysis raised the interest of many research groups and of the pharmaceutical industry. The development of CPU inhibitors as profibrinolytic agents is an attractive concept and possibilities for rational drug design will become more available in the near future due to the recently published crystal structure. Numerous studies have been performed and many of them show beneficial effects of CPU inhibitors for the improvement of endogenous fibrinolysis in different animal sepsis and thrombosis models. CPU inhibitors combined with t-PA seem to increase the efficiency of pharmacological thrombolysis allowing lower dosing of t-PA and subsequently fewer bleeding complications. This review will focus on recently obtained in vivo data and the benefits/risks of targeting CPU for the treatment of thrombotic disorders.

show abstract

Section: Clinical Utility Of Cpu Inhibition or A Role For Cpu In Vivo?mentioning

confidence: 99%